HLK 1001
Alternative Names: HLK-1001Latest Information Update: 28 Jan 2024
At a glance
- Originator HLK Pharmacin
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in USA
- 17 Dec 2020 HLK 1001 is available for licensing as of 17 Dec 2020. https://pharmacin.com/
- 17 Dec 2020 Clinical trials in Cancer in USA (HLK Pharmacin pipeline, December 2020)